8-K: Prelude Shifts Focus to Oral SMARCA2, Extends Runway

Prelude Therapeutics reports Q2 2025 financial results, pauses IV SMARCA2 degrader PRT3789 to focus on oral PRT7732, and extends cash runway into Q2 2026.

Summary

• Reported a net loss of $31.2 million, or $0.41 per share, for Q2 2025, an improvement from a net loss of $34.7 million, or $0.46 per share, in Q2 2024.
• Research and Development (R&D) expenses decreased to $25.8 million in Q2 2025 from $29.5 million in Q2 2024, primarily due to reduced SMARCA2 clinical trial costs.
• General and Administrative (G&A) expenses decreased to $6.4 million in Q2 2025 from $7.7 million in Q2 2024, mainly due to lower stock-based compensation.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $77.3 million as of June 30, 2025.
• The company anticipates its existing cash will fund operations into the second quarter of 2026.
• Development of the intravenous SMARCA2 degrader PRT3789 has been paused to focus solely on the oral SMARCA2 degrader PRT7732.
• PRT7732 is currently enrolling patients in its seventh dose escalation cohort (125 mg once daily) in a Phase 1 trial.
• An initial data update for PRT7732, including PK/PD, safety, and initial clinical activity, is expected by year-end 2025.
• The oral KAT6A degrader program is advancing a development candidate, with an Investigational New Drug (IND) filing on track for the first half of 2026.
• Preclinical data for mCALR-targeted ADCs and Precision ADCs with SMARCA2/4 dual degrader payloads were presented.

Sentiment

Score: 7

Explanation: The company reported a reduced net loss and lower operating expenses, extending its cash runway into Q2 2026, which are positive financial indicators. Strategic focus on the promising oral SMARCA2 degrader PRT7732, with rapid enrollment and positive early safety data, along with the advancement of the KAT6A degrader program towards IND filing, demonstrates strong pipeline execution. However, the decision to pause internal development of PRT3789 and the significant reduction in marketable securities indicate a need for disciplined capital management and potential future reliance on partnerships or capital raises.

Positives

• Net loss decreased to $31.2 million in Q2 2025 from $34.7 million in Q2 2024.
• R&D expenses decreased by $3.7 million and G&A expenses decreased by $1.3 million in Q2 2025 compared to Q2 2024, reflecting disciplined capital management.
• Cash runway extended into Q2 2026 with $77.3 million in cash, cash equivalents, restricted cash, and marketable securities.
• PRT7732, the oral SMARCA2 degrader, is advancing rapidly in its Phase 1 trial, currently enrolling the seventh dose cohort (125 mg once daily), with no dose-limiting toxicities or Grade 3+ related adverse events observed to date.
• The oral KAT6A degrader program is on track for an IND filing in the first half of 2026, with preclinical data showing picomolar potency, high selectivity, superior efficacy, and reduced bone marrow toxicity compared to dual inhibitors.
• Continued progress in the Precision ADC platform, including a partnership with AbCellera, and preclinical data supporting improved efficacy and tolerability.
• Preclinical data for mCALR-targeted Precision ADCs show robust anti-tumor activity and good tolerability.

Negatives

• The decision to pause further internal development of PRT3789, an intravenous SMARCA2 degrader, indicates a setback for that specific asset, with future advancement contingent on a partnership.
• The decrease in General and Administrative expenses was partly attributed to lower stock-based compensation due to a "lower valuation on more recent grants due to the decrease in our stock price," suggesting a decline in stock performance.
• Total current assets decreased significantly from $135.9 million at December 31, 2024, to $76.9 million at June 30, 2025, primarily due to a large reduction in marketable securities from $121.1 million to $47.5 million.
• Accumulated deficit increased from $(583.6) million at December 31, 2024, to $(646.9) million at June 30, 2025, reflecting ongoing losses.

Risks

• The timing and results of biotechnology development and potential regulatory approval are inherently uncertain.
• Ability to advance product candidates, receive regulatory designations/approvals, and commercialize product candidates.
• Clinical trial site availability and ability to enroll eligible patients.
• Supply chain and manufacturing facility risks.
• Ability to maintain and recognize benefits of certain designations received by product candidates.
• Ability to fund development activities and achieve development goals.
• Ability to protect intellectual property.

Future Outlook

The company expects to provide initial first-in-human data for PRT7732, including PK/PD, safety, and initial clinical activity, by year-end 2025. Final data from the Phase 1 study of PRT3789 is also anticipated by year-end 2025. An Investigational New Drug (IND) filing for the oral KAT6A degrader program is on track for the first half of 2026. The company's existing cash, cash equivalents, restricted cash, and marketable securities are projected to fund operations into the second quarter of 2026.

Management Comments

• Prelude demonstrated exemplary execution of our SMARCA2 program to deliver a potentially novel treatment option for patients with aggressive cancers harboring SMARCA4 deletion.
• We've decided to pause further development of PRT3789, and focus solely on PRT7732 as our go-forward strategy for our SMARCA2 Program.
• While PRT3789 demonstrated initial proof of concept for the mechanism, a number of considerations including the potential need for higher target coverage throughout the dosing interval, and capital needs to continue to advance both agents contributed to this decision.
• The clinical profile observed to date with PRT7732 including oral once daily dosing, safety and tolerability, oral exposures, and >90% target degradation positions us well to explore the potential for this mechanism in SMARCA4 deleted cancers and determine the path forward for continued development by year end.
• We've made significant progress across our core research and development organization, while employing disciplined capital management through resource allocation and headcount management throughout the Company.

Industry Context

The company operates in the precision oncology sector, focusing on novel drug candidates for high unmet needs in cancer patients. Its SMARCA2 degrader program targets SMARCA4-mutated cancers, which represent a significant unmet medical need due to poor prognosis and limited treatment options, including poor response to standard chemoimmunotherapy in NSCLC. The KAT6A degrader program addresses ER+ breast cancer, an area where existing inhibitors show promise but may have dose-limiting toxicities, positioning Prelude's selective degraders for improved efficacy and tolerability. The development of Precision ADCs and mCALR-targeted therapies aligns with broader industry trends towards targeted therapies and novel modalities to overcome limitations of traditional treatments and address "undruggable" targets.

Comparison to Industry Standards

• For SMARCA4-mutated NSCLC, the median progression-free survival for first-line chemoimmunotherapy is 2.7 months with response rates of approximately 22%, indicating a high unmet medical need that Prelude's SMARCA2 degraders aim to address.
• In the KAT6A program, Prelude's early degraders demonstrated superior monotherapy efficacy to a KAT6A/B dual inhibitor (e.g., Pfizer's PF-07248144) in preclinical models, achieving deep regressions and complete responses at lower doses, and showing potential for reduced bone marrow toxicity and neutropenia risk compared to dual inhibitors.
• Precision ADCs using Prelude's SMARCA degrader payloads demonstrated significantly better in vivo efficacy and tolerability when compared head-to-head against traditional cytotoxic ADCs (e.g., anti-PSMA cytotoxic ADC like Rosopatamab-MC-MMAF) in xenograft models.

Stakeholder Impact

• Shareholders: Potential for increased value if PRT7732 and KAT6A programs succeed; risk of dilution if future capital raises are needed; impact from stock price decrease mentioned in G&A explanation.
• Patients (SMARCA4-mutated cancers): Continued development of PRT7732 offers a potential new oral treatment option for aggressive cancers with high unmet need.
• Patients (ER+ breast cancer): Development of KAT6A degrader offers a potential new treatment option with improved tolerability.
• Employees: Disciplined capital management through resource allocation and headcount management suggests a focus on efficiency, which could imply stable or optimized workforce.
• Partners (AbCellera): Continued collaboration on Precision ADCs.

Next Steps

• Provide an initial first-in-human data update for PRT7732 (PK/PD, safety, initial clinical activity) by year-end 2025.
• Provide final data from the Phase 1 study of PRT3789 by year-end 2025.
• File an Investigational New Drug (IND) application for the oral KAT6A degrader program in the first half of 2026.
• Advance the first Precision ADC candidate in partnership with AbCellera in the second half of 2025.
• Continue to explore the potential for the SMARCA2 mechanism in SMARCA4 deleted cancers and determine the path forward for continued development of PRT7732 by year-end.

Key Dates

Recommendation

The company has demonstrated disciplined financial management by reducing operating expenses and extending its cash runway into Q2 2026, which provides stability. The strategic decision to focus resources on the oral SMARCA2 degrader PRT7732, which is showing promising early safety data and rapid enrollment, is a positive step towards optimizing the pipeline. The KAT6A degrader program also shows strong preclinical data and is on track for an IND filing. However, the discontinuation of internal development for PRT3789, while strategic, represents a setback for that specific asset and highlights the capital intensity of drug development. The significant decrease in marketable securities and the continued accumulated deficit indicate ongoing cash burn. Given the mix of positive clinical advancements and financial prudence alongside the strategic pipeline adjustment and continued losses, a "hold" recommendation is appropriate as investors await further clinical data readouts and clarity on future funding strategies.

Keywords

Precision Oncology, SMARCA2 Degrader, KAT6A Degrader, Cancer Therapy, Clinical Trials, Biotechnology, Oncology, Drug Development, SEC Filing, PRLD, SMARCA4, ADCs, Myelofibrosis, Essential Thrombocythemia, Breast Cancer, Lung Cancer